Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AMRXthis companyAmneal Pharmaceuticals, Inc.	$21.13	54.78×	-55.77×	1.31×	10.56×	-33.0%	37.6%	14.0%	2.4%	-101.8%	13.8%	6.8%	-38.65×	4.02×	1.75×	2.17×	0.0%	7	2.58	3	B
AMPHAmphastar Pharmaceuticals, Inc.	$28.74	12.75×	1.59×	1.74×	8.18×	241.3%	49.5%	19.5%	13.6%	12.4%	7.5%	9.7%	0.83×	2.29×	5.51×	4.02×	0.0%	6	2.19	4	A-
ANIPANI Pharmaceuticals, Inc.	$67.63	22.55×	2.93×	1.79×	7.83×	1187.9%	51.0%	9.2%	8.9%	14.5%	5.6%	9.5%	0.6×	0.19×	4.05×	2.71×	0.1%	7	2.58	3	B
CPIXCumberland Pharmaceuticals Inc.	$5.45	-20.95×	2.39×	1.34×	19.7×	-102.6%	85.0%	-6.3%	-6.4%	-11.4%	-6.9%	8.1%	0.41×	-0.43×	-5.63×	1.01×	0.0%	3	0.04	2	C
EBSEmergent BioSolutions Inc.	$6.03	12.61×	1.27×	0.89×	4.32×	-48.4%	47.2%	14.8%	7.1%	10.1%	5.9%	23.7%	1.09×	1.54×	1.86×	5.01×	0.0%	4	0.4	1	C-
INDVIndivior Pharmaceuticals Inc	$36.28	21.36×	-45.77×	3.62×	15.27×	-92.9%	80.1%	21.4%	16.9%	-214.3%	70.8%	-2.1%	-3.58×	0.51×	5.89×	0.71×	0.0%	7	3.7	2	C+
Peer median	—	12.75×	1.59×	1.74×	8.18×	-48.4%	51.0%	14.8%	8.9%	10.1%	5.9%	9.5%	0.6×	0.51×	4.05×	2.71×	0.0%	6	2.19	2	—